Biotechnology
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be…
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which…
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date…
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as…
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett's (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company's bottom…
Why Arbutus Biopharma stock dipped to 11-year low?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock plunged to an 11-year low of $1.31 on Monday due to considerable downside risk…
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a…
Earnings preview: Will losses continue for Celsion in Q2
Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market…
Progenics posts wider-than-expected loss in Q2
Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a…
What to look for when Progenics Pharma posts Q2 earnings
Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before…
Alnylam Pharmaceuticals posts narrower-than-expected Q2 loss
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported a wider loss in the second quarter of 2019 due to higher costs and expenses.…
Amgen beats Q2 earnings and revenue estimates
Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted…
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second…
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last…